Seelos Therapeutics Inc Stock Price, News & Analysis

Acadia Healthcare (NASDAQ: ACHC) announced that select facilities will participate in a trial studying suicidal ideation and behavior in major depression, sponsored by Seelos Therapeutics (NASDAQ: SEEL) for the SLS-002 drug. This drug, an intranasal ketamine, aims to address an unmet need for treating these conditions. The trial includes a five-dose treatment regimen over 15 days. Acadia's involvement underscores its mission to deliver innovative care, with promising preliminary results for SLS-002.

Seelos Therapeutics (SEEL) has announced the participation of Acadia Healthcare (ACHC) in a registration-directed Proof of Concept study for SLS-002, intranasal racemic ketamine, targeting Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD). This collaborative effort seeks to evaluate the efficacy and safety of SLS-002 in patients at imminent risk of suicide. Acadia operates a well-established network of behavioral health facilities, treating thousands daily, enhancing the study's potential impact.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the Guggenheim Nantucket Therapeutics Conference from September 27 to 29, 2022. CEO Raj Mehra will engage in 1x1 investor meetings and a fireside chat on September 28 at 2:45 PM ET, hosted by analyst Yatin Suneja. The company focuses on developing therapies for central nervous system disorders and rare diseases, with projects addressing various conditions including Major Depressive Disorder and amyotrophic lateral sclerosis. A webcast of the fireside chat is available online.

Seelos Therapeutics (Nasdaq: SEEL) announced participation in two key psychedelic conferences focusing on mental health treatments. The events, Jefferies Innovation in Mental Health Summit on September 22nd and Cantor Neurology and Psychiatry Conference on October 6th, will feature discussions about the clinical study of SLS-002, an intranasal racemic ketamine designed to treat suicidality in patients with Major Depressive Disorder. SLS-002 is noteworthy for being the only drug in its class currently in a registrational study targeting Acute Suicidal Ideation and Behavior.

Seelos Therapeutics (Nasdaq: SEEL) has been awarded a grant from The Michael J. Fox Foundation for Parkinson's Research to advance the preclinical development of its gene therapy, SLS-004. This program targets the SNCA gene, which is linked to alpha-synuclein expression and Parkinson's disease. Previous studies showed promising results with significant reductions in SNCA mRNA and protein levels. The CEO, Raj Mehra, emphasized the grant's importance in enhancing the program's visibility and impact. Further data from ongoing preclinical studies is expected later this year.

Seelos Therapeutics (Nasdaq: SEEL) announced the dosing of the first patient in an open-label study of SLS-005 for treating amyotrophic lateral sclerosis (ALS) in Australia. This 24-week study aims to assess the treatment's effectiveness and safety across multiple neurological disorders. The HEALEY ALS Platform trial is also actively enrolling, with full enrollment expected by the quarter's end. SLS-005 is a trehalose injection that shows promise in reducing protein misfolding and is currently investigational.

Seelos Therapeutics (Nasdaq: SEEL) announced a significant advancement in its gene therapy program SLS-004, showing a 19% downregulation of mRNA and a ~40% reduction of alpha-synuclein in an in vitro study targeting dementia with Lewy bodies (DLB). The results, with a statistical significance of p<0.01, support further preclinical studies. CEO Raj Mehra expressed excitement over the findings, emphasizing their potential efficacy, and indicated plans to release more detailed data in the second half of this year.

Seelos Therapeutics (Nasdaq: SEEL) announced on May 18, 2022, that it has received a Notice of Allowance from the USPTO for U.S. patent application number 16/833,515, covering SLS-007. This patent focuses on treating neurodegenerative diseases like Alzheimer's and Parkinson's by targeting alpha-synuclein aggregation. SLS-007 is being delivered via an adeno-associated virus in a preclinical study aimed at determining its pharmacokinetic and pharmacodynamic profiles. Preliminary data is anticipated in the second half of 2022.

Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the 2022 Jefferies Global Healthcare Conference from June 8-10, 2022. Raj Mehra, Ph.D., CEO, and Michael Golembiewski, CFO, will present on June 10 at 12:00 PM ET and engage in one-on-one meetings. This conference will host over 500 healthcare companies and 3,000 investors to discuss investment opportunities and trends in the healthcare sector. For additional details regarding the presentation, registration can be accessed here.